DE68917061D1 - O-glycosylierter IGF-1. - Google Patents

O-glycosylierter IGF-1.

Info

Publication number
DE68917061D1
DE68917061D1 DE68917061T DE68917061T DE68917061D1 DE 68917061 D1 DE68917061 D1 DE 68917061D1 DE 68917061 T DE68917061 T DE 68917061T DE 68917061 T DE68917061 T DE 68917061T DE 68917061 D1 DE68917061 D1 DE 68917061D1
Authority
DE
Germany
Prior art keywords
igf
glycosylated
glycosylated igf
expressed
obtaining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68917061T
Other languages
English (en)
Other versions
DE68917061T2 (de
Inventor
Anna Dr Skottner-Lundin
Linda Dr Fryklund
Par Dr Gellerfors
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia AB filed Critical Pharmacia AB
Application granted granted Critical
Publication of DE68917061D1 publication Critical patent/DE68917061D1/de
Publication of DE68917061T2 publication Critical patent/DE68917061T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE68917061T 1988-08-20 1989-08-17 O-glycosylierter IGF-1. Expired - Fee Related DE68917061T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888819826A GB8819826D0 (en) 1988-08-20 1988-08-20 Glycosylated igf-1

Publications (2)

Publication Number Publication Date
DE68917061D1 true DE68917061D1 (de) 1994-09-01
DE68917061T2 DE68917061T2 (de) 1994-11-17

Family

ID=10642464

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68917061T Expired - Fee Related DE68917061T2 (de) 1988-08-20 1989-08-17 O-glycosylierter IGF-1.

Country Status (15)

Country Link
US (1) US5273966A (de)
EP (2) EP0360411B1 (de)
JP (1) JP2543998B2 (de)
AT (1) ATE109206T1 (de)
AU (1) AU623675B2 (de)
CA (1) CA1335802C (de)
DE (1) DE68917061T2 (de)
DK (1) DK175360B1 (de)
ES (1) ES2060778T3 (de)
FI (1) FI102282B (de)
GB (1) GB8819826D0 (de)
IE (1) IE65096B1 (de)
NO (1) NO180636C (de)
NZ (1) NZ230383A (de)
WO (1) WO1990002198A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5612198A (en) * 1990-09-04 1997-03-18 The Salk Institute Production of insulin-like growth factor-1 in methylotrophic yeast cells
US5231178A (en) * 1991-01-16 1993-07-27 The Salk Institute Biotechnology/Industrial Associates, Inc. Method for the purification of intact, correctly-folded insulin-like growth factor-1
WO1992017595A1 (en) * 1991-04-01 1992-10-15 The Salk Institute Biotechnology/Industrial Associates, Inc. Genes which influence pichia proteolytic activity, and uses therefor
ES2097426T3 (es) * 1992-12-02 1997-04-01 Hoechst Ag Procedimiento para la obtencion de proinsulina con puentes de cistina correctamente unidos.
SE9402332D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab Igf-1
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
EP2032154A2 (de) * 2006-06-09 2009-03-11 Novartis Ag Stabilisierte insulin-artige wachstumsfaktor-polypeptide
EP2494050A4 (de) * 2009-10-30 2013-10-30 Merck Sharp & Dohme In glycoengineerter pichia pastoris hergestellter granulozytenkolonienstimulierender faktor
US20100172865A1 (en) * 2010-03-18 2010-07-08 Shantha Totada R Methods of enhancing hair growth
US8691771B2 (en) 2010-05-21 2014-04-08 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins for tissue repair
AU2014330853A1 (en) 2013-10-02 2016-02-25 National Institutes Of Health Insulin-like growth factor mimetics for use in therapy
EP3865147A1 (de) 2015-10-02 2021-08-18 Silver Creek Pharmaceuticals, Inc. Bispezifische therapeutische proteine zur gewebereparatur

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0123228B1 (de) * 1983-04-25 1993-09-29 Chiron Corporation Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren

Also Published As

Publication number Publication date
AU623675B2 (en) 1992-05-21
CA1335802C (en) 1995-06-06
FI910795A0 (fi) 1991-02-19
ES2060778T3 (es) 1994-12-01
JPH05505514A (ja) 1993-08-19
US5273966A (en) 1993-12-28
AU4051889A (en) 1990-03-23
ATE109206T1 (de) 1994-08-15
NO910669D0 (no) 1991-02-19
NO180636B (no) 1997-02-10
WO1990002198A1 (en) 1990-03-08
FI102282B1 (fi) 1998-11-13
DK175360B1 (da) 2004-09-13
IE892652L (en) 1990-02-20
NO180636C (no) 1997-05-21
FI102282B (fi) 1998-11-13
DE68917061T2 (de) 1994-11-17
EP0360411A1 (de) 1990-03-28
GB8819826D0 (en) 1988-09-21
JP2543998B2 (ja) 1996-10-16
EP0429502A1 (de) 1991-06-05
EP0360411B1 (de) 1994-07-27
NZ230383A (en) 1992-01-29
IE65096B1 (en) 1995-10-04
NO910669L (no) 1991-02-19
DK29491A (da) 1991-04-19
DK29491D0 (da) 1991-02-20

Similar Documents

Publication Publication Date Title
DK0402300T3 (da) Fremstilling i bakterier af gær og hæmoglobin og analoger dertil
FI851336L (fi) Ny fysiologiskt aktiv human polypeptid.
ATE107513T1 (de) Stabilisierte formulierungen mit hydrohoben proteinen.
DE68922602D1 (de) Polypeptide mit hormonwachstumsbefreiender wirkung.
ES2153444T3 (es) Anticuerpos contra interleucina-4 mamifera, y peptidos utiles como antigenos en su produccion.
ATE109206T1 (de) O-glycosylierter igf-1.
AU7184487A (en) Human g-csf protein expression
DE68929551D1 (de) Menschliche DNase
DE3689246T2 (de) Physiologisch aktives Polypeptid BUF-3.
ATE140483T1 (de) Natürlicher killerzellen-stimulationsfaktor
DK0454898T3 (da) Glycosaminoglycan-modificeret protein, fremgangsmåde til fremstilling af proteinet, farmaceutiske præparater indeholdende proteinet samt anvendelse af proteinet
DE3788004T2 (de) Verwendung von Tetrahydrocortisol in der Therapie von Glaukom.
IL80562A0 (en) Recombinant human lysozyme,its preparation by recombinant dna technology and pharmaceutical compositions containing it
DE3650790D1 (de) Menschlisches Interferon-Beta 2A zur Verwendung als Arzneimittel
ATE73462T1 (de) Hirudin-variante, deren verwendung und herstellung.
AU3902489A (en) Non-glycosylated, recombinant human IL2 in the reduced form, the process for obtaining it and its use as a medicament
EP0390849A4 (en) Methyl cellulose pharmaceutical composition
AU3327789A (en) Expression of the hiv 24 kda 24 gag protein in methylotrophic yeast
SE8802685D0 (sv) Stol
ATE98217T1 (de) Terpen-amino-alkohole und deren medizinische verwendung.
IE891349L (en) EXPRESSION OF THE HIV kDa GAG PROTEIN IN YEAST

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee